Global Common Cold Partnering 2010-2017

Publisher Name :
Date: 01-Sep-2017
No. of pages: 150
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Common Cold Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

- Trends in partnering deals

- Top deals by value

- Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Global Common Cold Partnering Terms and Agreements since 2010 report provides the reader with the following key benefits:

- In-depth understanding of deal trends since 2010

- Access to headline, upfront, milestone and royalty data

- Comprehensive access to multiple deals entered into by the world's biopharma companies since 2010

- Insight into key deal terms included in contracts, where disclosed

- Understand the key deal terms companies have agreed in deals

- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Common Cold Partnering 2010-2017

Table of Contents

Executive Summary

Chapter 1 - Therapy partnering trends in numbers
Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development

Chapter 2 - Most active dealmakers

Chapter 3 - Partnering deals directory
Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area

Chapter 4 - Partnering deals with a contract document

Chapter 5 - M&A in numbers
M&A in numbers - by year

Chapter 6 - M&A deals directory
M&A deals directory - by company A-Z
M&A deals directory - by deal value

Chapter 7 - Financing in numbers
Financing in numbers - by year
Financing in numbers - by financing type

Chapter 8 - Financing deals directory
Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering

List of Figures

Figure 1: Partnering frequency by year
Figure 2: Partnering most active
Figure 3: Partnering by industry sector
Figure 4: Partnering by deal type
Figure 5: Partnering by technology area
Figure 6: Partnering by stage of development
Figure 7: M&A frequency by year
Figure 8: Financing frequency by year
Figure 9: Financing by type
  • Global Drugs for Clostridium Difficile Infections Sales Market Report 2017
    Published: 15-Sep-2017        Price: US 4000 Onwards        Pages: 124
    In this report, the global Drugs for Clostridium Difficile Infections market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Drugs for Clostridium Difficile Infections for these regions, from 2012 to 2022 (forecast), covering - United Sta......
  • Global Polymixin Market Research Report 2017
    Published: 14-Sep-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Polymixin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Polymixin in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - ......
  • Global Cephalosporin Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 14-Sep-2017        Price: US 3480 Onwards        Pages: 118
    "Cephalosporin is an antibiotic medication commonly prescribed to treat several different types of infections. Cephalosporin originally derived from the fungus Acremonium, which was previously known as ""Cephalosporium""." Scope of the Report: This report focuses on the Cephalosporin in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions,......
  • Global Cefazolin Sodium Market Research Report 2017
    Published: 13-Sep-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Cefazolin Sodium market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cefazolin Sodium in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - J......
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 51
    Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever - Pipeline Review, H2 2017, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or house......
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 264
    Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Sign......
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 78
    Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape. Marburg hemorrhagic fever is a rare, acute infectious which affects both human and no......
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 74
    Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape. Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most comm......
  • Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017
    Published: 12-Sep-2017        Price: US 2000 Onwards        Pages: 151
    Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape. H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called av......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs